Drugs / INSULIN SUSP ISOPHANE RECOMBINANT HUMAN
INSULIN SUSP ISOPHANE RECOMBINANT HUMAN
also known as
human isophane insulin · human NPH insulin · Isophane insulin human suspension · NPH (neutral protamine Hagedorn) insulin · NPH human insulin · NPH insulin
Protein / enzyme biologic targets INSR via activation
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00653341 | Jan 2000 → Oct 2001 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INSULIN SUSP ISOPHANE RECOMBINANT HUMAN | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201540 ↗ |
| Known as | human isophane insulin | “NPH insulin (human isophane insulin)” PMID 33166419 ↗ Nov 2020 |
| Known as | human NPH insulin | “human NPH insulin” PMID 14578243 ↗ Nov 2003 |
| Known as | Isophane insulin human suspension | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201540 ↗ |
| Known as | NPH (neutral protamine Hagedorn) insulin | “NPH (neutral protamine Hagedorn) insulin (human isophane insulin)” PMID 33166419 ↗ Nov 2020 |
| Known as | NPH human insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00653341 ↗ |
| Known as | NPH insulin | “human NPH insulin” PMID 14578243 ↗ Nov 2003 |
| Action | Activate | “Insulin receptor agonist” CHEMBL1201540 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL1201540 ↗ |
| Target | INSR | “Insulin receptor agonist” CHEMBL1201540 ↗ |